| Results demonstrate that FAM83D has prognostic value for breast cancer patients and is a novel oncogene in breast cancer development that at least in part acts through mTOR hyper-activation by inhibiting FBXW7. | breast, |
| Taken together, these results demonstrate that FAM83D is a novel oncogene in HCC development and may constitute a potential therapeutic target in HCC. | liver, |
| FAM83D activates the MEK/ERK signaling pathway and promotes cell proliferation in hepatocellular carcinoma. | liver, |
| FAM83D promotes cell proliferation and motility by downregulating tumor suppressor gene FBXW7. | None |